P80.01 A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC

Abstract

of aspartate transaminase and alanine aminotransferase (grade II CTCAE5.0). Patient B was diagnosed as adenocarcimoma with clinical stage III A (T1bN2M0). The evaluation of CT was stable disease (SD)(Fig. 1(e)(f)(g)(h)). The pathological response rate was 30%. Pathological stage reduced to stage II B (pT1cN1M0). Treat-related AE was leukopenia (grade II CTCAE5.0). All adverse reactions can be returned to normal after symptomatic treatment. Conclusion:Neoadjuvant Sintilimab plus chemotherapy showed a bright efficacy with no intolerable adverses. It may improve the downstage rate and pathologic remission rate of patients with NSCLC. Whether it can improve the DFS and OS of patients remains to be further observed with experimental data.